For example, the amplification or over-expression of the ErbB2 (HER2/neu) oncogene, that enhances various growth-related signaling activities [5] from receptor-level to effector-level [4], is commonly found in about 25% of breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.